|
Therapies
and Clinical Usage
| |
Dietary
Therapy |
Drug
Treatment |
| Initiation
Level |
LDL
Goal |
Consideration
Level |
LDL
Goal |
| Without
CHD & less than 2 Risk Factor |
>160
mg/dl |
<160
mg/dl |
>190
mg/dl |
<160
mg/dl |
| Without
CHD & 2 or More Risk Factors |
>130
mg/dl |
<130
mg/dl |
>
160 mg/dl |
<130
mg/dl |
| With
CHD |
>100
mg/dl |
<100
mg/dl |
>130
mg/dl |
<100
mg/dl |
| Lipoprotein
Property |
Lipid
Modifying Drugs |
| Nicotinic
Acid |
Statins |
Fibrates |
Resins |
Combination
of Nicotinic Acid and Statin |
| HDL
levels |
Increase |
Increase |
Increase |
No
Change |
Increase |
| Average,
25%-40% |
3% - 10% |
TG <500 (3%-5%) |
|
|
Average, 35% |
| Range,
0%-100% |
|
TG >1,000
(35%) |
|
|
|
| Triglyceride
levels |
Decrease |
Decrease |
Decrease |
No change
to increase |
Decrease |
| Average, 30%-70% |
TG <500 (10%-30%) |
TG <500 (25%) |
|
Average, 75% |
| Range, 0%-90% |
TG >1,000
(40%-50%) |
TG >1,000
(65%-80%) |
|
|
| LDL
particle density |
Decrease in
dense (pattern B) LDL by up to 90% |
Decrease in
dense (pattern B) LDL |
Increase in
dense (pattern B) by 15% to 150% |
Decrease in
dense (pattern B) LDL |
Decrease in
dense (pattern B) LDL Average, 80% to 90% |
| Increase in
buoyant (pattern A) LDL by up to 20% |
Dramatic decrease
in buoyant (pattern A) LDL |
Increase in
buoyant (pattern A) LDL by 25% to 140% |
Increase in
buoyant (pattern A) LDL |
Decrease in
buoyant (pattern A) LDL |
| Lp(a)
levels |
Decrease |
No Change |
No Change |
No Change |
Decrease |
| Average, 15%
to 35% |
|
|
|
Average, 15%
to 35% |
| Range, 0%
to 50% |
|
|
|
|
|
